EP Patent

EP3682884A1 — Crystal form of gsk1278863 and preparation method and pharmaceutical use thereof

Assigned to GlaxoSmithKline Intellectual Property No 2 Ltd · Expires 2020-07-22 · 6y expired

What this patent protects

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

USPTO Abstract

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3682884A1
Jurisdiction
EP
Classification
—
Expires
2020-07-22
Drug substance claim
No
Drug product claim
No
Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.